Loading…
ATENOLOL is a brand name for Atenolol. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: 1) For the management of hypertension, angina pectoris and cardiac arrhythmias. 2) For early intervention in the acute phase of myocardial infarction.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology The dosage should be determined on an individual basis. It is recommended to start with the lowest possible dosage so that heart failure, bradycardia and bronchial symptoms are noticed timely. This is especially important in elderly.
, once a week) under controlled conditions or based on the clinical effect.
Adults and children over 12 years:
Hypertension: A starting dose of 25mg is recommended. The usual maintenance dosage in hypertension is one tablet (50-100mg) daily. The maximum effect will be reached after 1-2 weeks. : a diuretic. Angina pectoris: 50-100mg daily, depending on the clinical effect, in order to obtain a heartbeat in rest of 55-60 beats per minute.
Increasing the dose above 100mg daily does not generally lead to an increased antianginous effect. If desired the dosage of 100mg daily can be divided in two dosages.
Dysrhythmias:
Initially controlled intravenously. A suitable oral maintenance dosage is 50-100mg daily, given as a single dose.
Secondary prevention after myocardial infarction:
Initially controlled intravenously, followed by 50mg orally about 10 minutes after the intravenous dose provided no adverse effects occur. This should be followed by a further 50mg orally 12 hours later. Maintenance dose is 100mg daily in 1-2 dosages for 6 days or until discharge from hospital.
The Elderly:
Dosage requirements may be reduced, especially in patients with impaired renal function. Dosage should be titrated according to clinical effect.
Children under 12 years:
Atenolol is not recommended for use in children under 12 years of age.
Impaired renal function:
Atenolol is excreted via the kidneys, therefore the dosage will need to be adjusted in severe renal conditions. GFR (mL/min/1,73 m2 BSA) Recommended daily dose atenolol (mg/day) >35 No dose adjustment necessary 15-35 25-50 (or 50-100 every second day) <15 25-50 every second day In haemodialysis a 50mg tablet is administered after each dialysis.
Atenolol is well tolerated. In clinical studies, the undesired events reported are usually attributable to the pharmacological actions of atenolol. The following undesired events, listed by body system, have been reported with the following frequencies: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to < 1/100), rare (≥1/10000 to <1/1000), very rare (<1/10000) including isolated reports, not known (cannot be estimated from the available data).
Blood and Lymphatic System Disorders Rare:
Thrombocytopenia, purpura Psychiatric Disorders Uncommon: Sleep disturbances of the type noted with other beta-blockers Rare: Hallucinations, psychoses, confusion, mood changes and nightmares Nervous System Disorders Rare: Dizziness, headache, paraesthesia Eye Disorders Rare: Dry eyes, visual disturbances Cardiac Disorders Common: Bradycardia Rare: Heart failure deterioration, precipitation of heart block Vascular Disorders Common: Cold extremities Rare: Postural hypotension which may be associated with syncope, increase of an existing intermittent claudication, in susceptible patients Raynaud's phenomenon Respiratory, Thoracic and Mediastinal Disorders Rare: Bronchospasm may occur in patients with bronchial asthma or a history of asthmatic complaints Gastrointestinal Disorders Common: Gastrointestinal disturbances Rare: Dry mouth Hepatobiliary Disorders Uncommon: Elevations of transaminase levels Rare: Hepatic toxicity including intrahepatic cholestasis Skin and Subcutaneous Tissue Disorders Rare: Skin rashes, exacerbation of psoriasis, alopecia, psoriasiform skin reactions Unknown: Hypersensitivity reactions, including angioedema and urticaria Musculoskeletal and Connective Tissue Disorders Not known: Lupus-like syndrome Reproductive System and Breast Disorders Rare: Impotence General Disorders and Administration Site Conditions Common: Fatigue Investigations Very rare: An increase in Antinuclear Antibodies (ANA) has been observed, however the clinical relevance of this is not clear Discontinuance of the drug should be considered if, according to clinical judgement, the well-being of the patient is adversely affected by any of the above reactions.
This medicine, as with other beta-blockers:
Should not be withdrawn abruptly. The dosage should be withdrawn gradually over a period of 7–14 days, to facilitate a reduction in beta-blocker dosage. Patients should be followed during withdrawal, especially those with ischaemic heart disease.
When a patient is scheduled for surgery, and a decision is made to discontinue beta- blocker therapy, this should be done at least 24 hours prior to the procedure. The risk- benefit assessment of stopping beta-blockade should be made foreach patient.
If treatment is continued, an anaesthetic with little negative inotropic activity should be selected to minimise the risk of myocardial depression. The patient may be protected against vagal reactions by intravenous administration of atropine.
3), may be used in patients whose signs of heart failure have been controlled. Caution must be exercised in patients whose cardiac reserve is poor. May increase the number and duration of angina attacks in patients with Prinzmetal's angina due to unopposed alpha-receptor mediated coronary artery vasoconstriction.
Atenolol is a beta1-selective beta-blocker; consequently, its use maybe considered although utmost caution must be exercised. 3), may also aggravate less severe peripheral arterial circulatory disturbances. Due to its negative effect on conduction time, caution must be exercised if it is given to patients with first-degree heart block.
May mask the symptoms of hypoglycaemia, in particular, tachycardia. Beta-blockers could further increase the risk of severe hypoglycaemia when used concurrently with sulfonylureas. Diabetic patients should be advised to carefully monitor blood glucose levels.
5). May mask the signs of thyrotoxicosis. Will reduce heart rate as a result of its pharmacological action. In the rare instances when a treated patient develops symptoms which may be attributable to a slow heart rate and the pulse rate drops to less than 50–55 bpm at rest, the dose should be reduced.
1 • Cardiogenic shock • Uncontrolled heart failure • Sick sinus syndrome • Second-or third-degree heart block • Untreated phaeochromocytoma • Metabolic acidosis • Bradycardia (heart rate less than 45 beats per minute) • Hypotension • Severe peripheral arterial circulatory disturbances
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Atenolol in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
The administration should be done in hospital since sudden decrease of the arterial pressure may occur.
Decreased hepatic function:
No dose adjustment is necessary. Method of Administration For oral administration.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
May cause a more severe reaction to a variety of allergens when given to patients with a history of anaphylactic reaction to such allergens. Such patients may be unresponsive to the usual doses of adrenaline (epinephrine) used to treat the allergic reactions.
May cause a hypersensitivity reaction including angioedema and urticaria. 2). 73 m2. Although cardioselective (beta1) beta-blockers may have less effect on lung function than non-selective beta-blockers, as with all beta-blockers, these should be avoided in patients with reversible obstructive airways disease, unless there are compelling clinical reasons for their use.
Where such reasons exist, atenolol may be used with caution. Occasionally, some increase in airways resistance may occur in asthmatic patients however, and this may usually be reversed by commonly used dosage of bronchodilators such as salbutamol or isoprenaline.
As with other beta-blockers, in patients with a phaeochromocytoma, an alpha-blocker should be given concomitantly.
Patient information leaflets and labels will carry the following warnings:
Patient Information Leaflet: If you have ever had asthma or wheezing, do not take this medicine without first checking with your doctor.
Labels:
Do not take this medicine if you have a history of wheezing or asthma. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.